Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

VB-111 + Paclitaxel

Name
ofranergene obadenovec
Target
pro-apoptotic Fas-tumor necrosis factor receptor 1 (TNFR1)
FDA Approved
No
Ema approved
Status
0

1 clinical trial

2 drugs

1 abstract

1 indication

Indication
Platinum Resistant Ovarian Cancer
Drug
VB-111
Drug
Tiragolumab
Clinical trial
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Status: Completed, Estimated PCD: 2022-07-19
Abstract
Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).
Org: HonorHealth Research Institute, Duke Cancer Institute, Chaim Sheba Medical Center, University of Cincinnati Cancer Institute, International Drug Development Institute,